Monopar Therapeutics Inc Stock Price, News & Analysis

Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes have expanded their collaboration in the radiopharmaceutical sector, introducing a new imaging candidate, MNPR-101-Zr. Preclinical results indicate high uptake of MNPR-101-Zr in various tumors, supporting plans for a first-in-human imaging study by year-end. MNPR-101-Zr is a zirconium-89 labeled form of MNPR-101, targeted at the urokinase plasminogen activator receptor (uPAR). The partnership aims to leverage MNPR-101 for both imaging and therapeutic applications, highlighting the potential of personalized medicine in cancer treatment.

Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced an update on its Phase 1b trial of camsirubicin for advanced soft tissue sarcoma (ASTS). Enrollment has begun for the fifth dose cohort at 650 mg/m², nearly 2.5 times the highest dose previously evaluated. Notably, there has been no drug-related cardiotoxicity observed, in contrast to doxorubicin, the current standard treatment. Additionally, lower rates of hair loss and oral mucositis have been reported in patients treated with camsirubicin compared to those on doxorubicin. A second clinical trial site has also been established at the Fred Hutchinson Cancer Center in Seattle.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced plans to report key clinical updates over the next two months, focusing on:

• Interim analysis for the Validive Phase 2b/3 VOICE trial
• Clinical data from the camsirubicin Phase 1b trial
• Preclinical progress on the MNPR-101 RIT program

Notably, the camsirubicin Phase 1b trial has shown improved safety compared to doxorubicin, while enrollment for Validive's trial continues ahead of its expected analysis in March 2023. These updates are crucial for assessing the company's therapeutic pipeline aimed at improving cancer patient outcomes.

Monopar Therapeutics Inc. (Nasdaq: MNPR) received a positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m²) in its camsirubicin Phase 1b trial for advanced soft tissue sarcoma (ASTS). This decision follows safety reviews from prior doses, indicating the drug's favorable safety profile compared to doxorubicin. The trial aims to improve progression-free survival, showing promise based on earlier studies. Camsirubicin, a novel analog of doxorubicin, has not shown the cardiotoxicity linked to the original drug in earlier trials, making it a significant advancement in treatment options for ASTS.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced promising preclinical data for its drug candidate MNPR-202, developed in collaboration with the Cancer Science Institute of Singapore. MNPR-202, a DNA Damaging Response drug akin to doxorubicin, demonstrates comparable cytotoxic potency while evading resistance in certain tumors. The findings, showcased at the ASH Annual Meeting, suggest that MNPR-202 may enhance immune activation and offer superior results in combination regimens. This positions MNPR-202 as a potential disruptor in the chemotherapy landscape for various cancers.

Monopar Therapeutics (MNPR) announced promising results from its ongoing Phase 1b trial of camsirubicin for advanced soft tissue sarcoma, presented at the CTOS Annual Meeting. The trial has enrolled 11 patients, with 5 of 10 showing stable disease at 12 weeks. Camsirubicin aims to enhance efficacy while minimizing cardiac damage compared to doxorubicin, the current standard. The trial is currently escalating doses, with no drug-related cardiotoxicity observed so far, emphasizing its potential for improved patient outcomes.

Monopar Therapeutics (MNPR) reported its Q3 2022 financial results, revealing cash reserves of $14.3 million, which will fund ongoing clinical trials through at least November 2023. The VOICE trial for Validive is on track with its Phase 2b/3 interim analysis scheduled for Q1 2023. Meanwhile, early data from the Camsirubicin trial will be presented at CTOS 2022. The company’s Q3 net loss was $2.4 million ($0.19 per share), with a slight decrease in R&D expenses but an increase in G&A expenses. Monopar plans to seek additional funding within the next year.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced plans to present clinical data on camsirubicin and preclinical data on MNPR-202 in the upcoming months. Key events include the presentation of camsirubicin Phase 1b data at the CTOS Annual Meeting from November 16-19, 2022, in Vancouver, and preclinical data on MNPR-202 at the ASH Annual Meeting from December 10-13, 2022, in New Orleans. Additionally, the company will report its interim analysis for the Validive Phase 2b/3 VOICE trial in Q1 2023, with ongoing patient enrollment at 71 sites.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that its drug candidate MNPR-202 will be presented at the 64^th ASH Annual Meeting & Exposition in New Orleans. This presentation marks the initial data release from the collaboration with Dr. Anand Jeyasekharan, focusing on MNPR-202's effects on DNA damage response in cancer cells. Designed for potential use against cancers resistant to doxorubicin, MNPR-202 aims to enhance therapeutic options. CEO Chandler Robinson expressed optimism about the collaboration's progress and the anticipated findings.